Panel Nixes Tolvaptan On Weak Efficacy Data And Liver Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
Small, unclear drug effect and hepatotoxicity take down Otsuka’s tolvaptan kidney disease indication at Cardiovascular and Renal Drugs Advisory Committee review.